Articles
Agenix to divest business in China
Divesting business in China will allow Agenix to focus on its diagnostics projects. [ + ]
Antarctica's promiscuous microbes
Deep Lake, located 5 km from Davis Station in Antarctica, is 3500 years old, 36 m deep and so salty that it remains in liquid form down to a temperature of -20°C. Researchers have now uncovered the secrets of the lake's dominant inhabitants - extremophile microbes from the haloarchaea group. [ + ]
CO2 causes turf wars
The planet is warming, but Dr Marilyn Ball’s research group has found that rising carbon dioxide in the atmosphere makes cold-tolerant plants more susceptible to frost. [ + ]
New hepatitis virus or glassware contaminant?
The sensitivity of next-generation sequencing can be fantastic and also problematic as the system can easily pick up contaminants and lead researchers into false conclusions. [ + ]
Better salaries and employment prospects for US chemists
Each year the American Chemical Society surveys its members to gain a snapshot of their employment and salaries. This year's survey has found that 2013 is looking much better for chemists and chemical engineers in the US as both employment and salaries are increasing. [ + ]
First Parkinson's patient implanted with LCT's NTCELL
The first Parkinson's patient has been implanted with Living Cell Technologies' (ASX:LCT) NTCELL regenerative treatment during a phase I trial. [ + ]
Allied's CardioCel stands the test of time
Allied Healthcare (ASX:AHZ) said paediatric heart defect patients treated using its CardioCel tissue patch have shown no sign of calcification at the site of repair after up to five years of monitoring. [ + ]
Lymphatic mispatterning
Natasha Harvey will head to ComBio this year with a few years’ worth of results and an exciting new story of a protein called Nedd4 and how it could hold a key to vascular networks and their problems. [ + ]
Innate Immunotherapeutics plans move across Tasman
New Zealand biopharmaceutical company Innate Immunotherapeutics will migrate across the Tasman this month in a bid to get its Phase IIb trial financed and underway in Australia. [ + ]
Why some people don't get as sick and a universal flu vaccine
Investigating why some people seem to resist severe illness has led scientists closer to developing a universal flu vaccine. [ + ]
Insect resistance and transgenic crops
Many transgenic crops synthesise their own pesticides, usually a toxic protein is synthesised in stems and leaves. Pests attempting to eat the crop are killed while those not attacking the crop are completely unaffected. A pretty nifty solution but now examples are emerging of pests developing resistance to the toxin as a dominant trait. [ + ]
Bioniche to raise $10m through equity offer
Bioniche (ASX:BNC) has launched a $10m capital raising in Canada to ensure it has funds to continue development of cancer treatment Urocidin while it sells its animal health unit. [ + ]
Viralytics meets primary goal of melanoma trial
A phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint. [ + ]
Be a part of the first Australian world brain mapping congress: call for papers and registrations open
For the first time in Australia, all disciplines involved in brain mapping and therapies will gather at the one conference when the 11th Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT Congress) comes to Sydney early next year. [ + ]
Microalgae, bacteria and a bioreactor
A solution to a major problem - arsenic poisoning from natural groundwater - may be within reach thanks to Australian research. [ + ]

